Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT05699902 Not yet recruiting - Pain, Postoperative Clinical Trials

Pectoral Nerve Block During Mastectomy

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Impact of pectoral nerve block on postoperative pain and quality of recovery in patients undergoing breast cancer surgery: A prospective study

NCT ID: NCT05699577 Not yet recruiting - Clinical trials for Breast Cancer Female

Prognostic Value of Some Biochemical Markers in Breast Cancer

Start date: February 2023
Study type: Observational

breast cancer is the most common type of cancer in women and first cause of cancer death among them. in Egypt it constitutes 33% of female cancer cases and more than22000 new cases diagnosed each year. there are many prognostic factors for breast cancer as Tumer size, axillary lymph node status, hormonal receptor status, and tumer markers as Ca15-3 and interferon gamma.

NCT ID: NCT05698056 Active, not recruiting - Breast Cancer Clinical Trials

A Retrospective Analysis of Magnetic Resonance Imaging Data for Breast Cancer Screening in the Open Consortium for Decentralized Medical Artificial Intelligence

Start date: January 1, 2023
Study type: Observational

ODELIA is a project that aims to improve breast cancer detection in magnetic resonance imaging by utilizing artificial intelligence and swarm learning (MRI). The project will create an open-source swarm learning software framework that will be used to train AI models for breast cancer detection. These models' performance will be compared to that of conventional AI models, and the results will be used to assess the effectiveness of swarm learning in improving the accuracy and robustness of AI models. The project will use retrospective, anonymized breast MRI datasets with manual ground truth labels for cancer presence. The study is not associated with any patient treatment or intervention. The project's goal is to provide evidence of the clinical benefits of swarm learning in the context of breast cancer screening, such as accelerated development, improved performance, and robust generalizability.

NCT ID: NCT05697198 Recruiting - Breast Cancer Clinical Trials

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

Start date: April 19, 2021
Study type: Observational [Patient Registry]

The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next generation sequencing of time-matched or archival tissue specimens from individuals with advanced solid tumors. Examples of locally advanced and metastatic tumors include stage III and IV cancers (ex. lung, breast, all gastrointestinal malignancies, all gynecologic malignancies, prostate cancer, head and neck tumors, soft tissue cancers, and melanoma). These specimens will be analyzed for diagnostic purposes and research (either by Labcorp/OmniSeq or to a third-party recipient designated by Labcorp/OmniSeq). Labcorp/OmniSeq may transfer the specimens and data to its clients, including commercial, academic or non-profit research institutions; or alternatively, may retain the specimens in its repository for future research use at the sole discretion of Labcorp/OmniSeq and or assignees. Labcorp/OmniSeq will maintain all detailed clinical information including demographic data (de-identified), ethnicity, disease state, stage (radiological, pathological and clinical-whichever is relevant).

NCT ID: NCT05697146 Recruiting - Breast Cancer Clinical Trials

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

Start date: December 15, 2022
Study type: Observational

This study is a national, multicenter, prospective, non-interventional study in women with HR+/HER2- locally advanced or metastatic breast cancer (BC), for which a prior clinical decision to initiate ribociclib + endocrine therapy (ET) treatment according to the marketing authorization has been taken and was taken independent and prior to study participation decision.

NCT ID: NCT05695859 Enrolling by invitation - Clinical trials for Breast Cancer Female

99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy

Start date: December 20, 2022
Study type: Observational

An open-label, single center study with 99mTc-DARPinG3 SPECT/CT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 99mTc-DARPinG3 SPECT/CT and standard histopathology from relevant tumor and lymph node biopsies.

NCT ID: NCT05695313 Not yet recruiting - Breast Cancer Clinical Trials

Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

This study recommends the use of OnLife dietary supplement, which will be followed by a few day before the initiation of PACLITAXEL, for the prevention of PACLITAXEL induced neuropathy. OnLife will be continued one month after stopping chemotherapy. This would limit the number of PACLITAXEL dose reductions and premature interruptions of this chemotherapy, thus potentially improving the results in terms of antitumor efficacy, while improving the quality of life of patients treated with weekly PACLITAXEL.

NCT ID: NCT05694559 Recruiting - Breast Cancer Clinical Trials

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics

Start date: November 23, 2022
Phase: N/A
Study type: Interventional

To identify Black individuals who are eligible for genetic testing through trusted community organizations, and to connect Black individuals and their families to genetic testing and counseling so that they can know their cancer risk and how to decrease it.

NCT ID: NCT05692674 Recruiting - Breast Cancer Clinical Trials

A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction

Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

The incidence of breast reconstruction failure after conventional photon radiotherapy for breast cancer is about 18.7%. At present, there is limited data on proton radiotherapy for post operative breast cancer with implantation reconstruction. Proton radiotherapy for breast cancer can significantly reduce the radiation dose of the ipsilateral heart and lung, thereby reducing the incidence of cardiac events and radiation pneumonia. This study is aimed at the study of adjuvant hypofractionated intensity-modulated proton radiotherapy for post operative breast cancer with implantation reconstruction. It can provide an ideal treatment option for such patients to effectively protect the heart and lungs without increasing the failure rate of breast reconstruction after adjuvant radiotherapy.

NCT ID: NCT05690828 Not yet recruiting - Breast Cancer Clinical Trials

Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer.

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Medical progress in the treatment of cancer has prolonged patients' life expectancy. This improvement has led researchers to become concerned about the long-term negative effects of cancer treatments on quality-of-life. In particular, previous studies have identified complaints that have been submitted concerning the cognitive status of patients treated with chemotherapy (Berglund et coll., 1991). All of these cognitive changes are collectively grouped under the term chemobrain. The consequences of treatments remain however underestimated, as the priority when diagnosing cancer remains the patient's short- to medium-term survival; yet, quality-of-life contributes to the long-term survival of patients (Kramer, 2000). In addition to medical treatments, psychosocial care adapted to the specific needs of subjects is thus important for improving their quality-of-life and helping them return to work. Even if initiatives have multiplied over the past few decades in the psychosocial management of these subjects (e.g., supportive care), that related to cognitive disorders in subjects having survived cancer remains a little documented field. Cognitive deficiency in cancer survivors is said to be moderate (Razaq et coll., 2017), which makes survivors ideal candidates for cognitive rehabilitation.